Shift4Good

Shift4Good is a London-presence European cleantech-focused venture fund that increasingly evaluates biological and health-adjacent sustainable technologies, with healthcare-relevant exposure in deep tech and biotech. The fund’s core thesis centers on the energy and sustainability transition, but its investment scope has broadened over time to include biology-based platforms whose work contributes to climate, food, or planetary health outcomes. As such, the firm is not a healthcare specialist and does not market an AI-specific focus, and limited public information is available about specific named investment partners attached to health-adjacent biotech deals within Shift4Good.

The fund invests at Series A and Series B stages, with equity checks in the $1M to $5M range, typically participating in syndicates rather than acting as the sole healthcare-specialist lead. Geographic focus spans Europe broadly, with deal flow concentrated in companies aligned to the climate and sustainability mandate. Co-investment alongside dedicated climate funds, deep tech specialists, and selective generalist growth investors is common.

For founders, Shift4Good is most relevant when a biotech or deep tech company has a credible sustainability or climate impact narrative alongside its core scientific or commercial thesis. CEOs should expect diligence to engage substantively with environmental impact metrics in addition to standard commercial criteria. Companies focused on traditional human therapeutics, clinical care delivery, or healthcare software without a sustainability component will find better fits with healthcare-specialist investors. For European biotech and deep tech founders working at the intersection of biology and planetary health, Shift4Good represents an aligned mid-stage capital partner.